Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1966]

ASCO 2025: Latest in EGFR positive NSCLC

Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard

ASCO 2025: Latest in EGFR positive NSCLC ( Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard )

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for...

Dr Michael B. Atkins - Georgetown Lombardi Comprehensive Cancer Center...

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma ( Dr Michael B. Atkins - Georgetown Lombardi Comprehensive Cancer Center, Washington, USA )

BCG combined with mitomycin offers improved adjuvant treatment regimen for high...

Prof Dickon Hayne - University of Western Australia, Perth, Australia

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC ( Prof Dickon Hayne - University of Western Australia, Perth, Australia )

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received...

Prof Thomas Powles - Barts Cancer Institute, London, England

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received perioperative durvalumab ( Prof Thomas Powles - Barts Cancer Institute, London, England )

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Prof Thomas Powles - Barts Cancer Institute, London, England

Sasanlimab BCG combo improves outcomes in high-risk NMIBC ( Prof Thomas Powles - Barts Cancer Institute, London, England )

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna...

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

Treatment with BAY 2927088 led to durable responses in patients previously...

Prof Nicolas Girard - Institut Curie, Paris, France

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible...

Dr Sarah Psutka - University of Washington, Seattle, USA

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )

Challenges of managing patients with NMIBC: from risk stratification to...

Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat

Challenges of managing patients with NMIBC: from risk stratification to treatment and beyond ( Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

CaboNivo shows sustained long-term benefits for survival and tumour progression...

Prof Camillo Porta - University of Bari, Bari, Italy,

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta - University of Bari, Bari, Italy, )

More from ecancer